Pack size | 10 Ml |
Treatment | Cancer |
Prescription/Non prescription | Prescription |
Packaging Size | 10 Ml |
Form Of Medicine | Injection |
Shelf life | more than 12- 24 months |
Strength | 100mg |
Minimum Order Quantity | 10 vials |
Salt Name | Daratumumab |
Drug Name | Daratumumab Injection |
Compostion | Daratumumab 100 MG/20 MG Injection |
Daratumumab is a monoclonal antibody that blocks a certain protein in the body that can affect tumor cell growth. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.Daratumumab injection is used alone or together with other medicines to treat multiple myeloma (a type of bone marrow cancer). It is used alone in patients who have received at least 3 prior treatments that did not work well, including a proteasome inhibitor and an immunomodulatory agent, or who did not respond to both a proteasome inhibitor and an immunomodulatory agent.Daratumumab injection is also used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, to treat patients with multiple myeloma who have received at least 1 previous treatment.
Pack size | 10 Ml |
Treatment | Cancer |
Prescription/Non prescription | Prescription |
Packaging Size | 10 Ml |
Form Of Medicine | Injection |
Shelf life | more than 12- 24 months |
Strength | 100mg |
Minimum Order Quantity | 10 vials |
Salt Name | Daratumumab |
Drug Name | Daratumumab Injection |
Compostion | Daratumumab 100 MG/20 MG Injection |
Daratumumab is a monoclonal antibody that blocks a certain protein in the body that can affect tumor cell growth. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.Daratumumab injection is used alone or together with other medicines to treat multiple myeloma (a type of bone marrow cancer). It is used alone in patients who have received at least 3 prior treatments that did not work well, including a proteasome inhibitor and an immunomodulatory agent, or who did not respond to both a proteasome inhibitor and an immunomodulatory agent.Daratumumab injection is also used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, to treat patients with multiple myeloma who have received at least 1 previous treatment.